ReviewTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016
Targeting cancer stem cell-specific markers and/or associated signaling pathways for overcoming cancer drug resistance.
Review in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- Anticancer potential of Thymoquinone from Nigella sativa L.: An in-silico and cytotoxicity study.PloS one · 2025Article
- Dualistic Effects of PRKAR1A as a Potential Anticancer Target in Cancer Cells and Cancer-Derived Stem Cells.International journal of molecular sciences · 2024Article
- Advances and Challenges in Cancer Stem Cells for Onco-Therapeutics.Stem cells international · 2023Review
- A systematic approach introduced novel targets in rectal cancer by considering miRNA/mRNA interactions in response to radiotherapy.Cancer biomarkers : section A of Disease markers · 2022Article
- Engineered multifunctional nanocarriers for controlled drug delivery in tumor immunotherapy.Frontiers in oncology · 2022Review
- Targeting hypoxia-induced tumor stemness by activating pathogen-induced stem cell niche defense.Frontiers in immunology · 2022Article
- Interplay of autophagy and cancer stem cells in hepatocellular carcinoma.Molecular biology reports · 2021Review
- Impact of Primary Site Surgery on Survival of Patients with de novo Stage IV Breast Cancer.Cancer management and research · 2021Article
- A Concise Review: The Role of Stem Cells in Cancer Progression and Therapy.OncoTargets and therapy · 2021Review
- Effects of salinomycin and niclosamide on small cell lung cancer and small cell lung cancer circulating tumor cell lines.Investigational new drugs · 2020Article
- The Deubiquitinase USP4 Stabilizes Twist1 Protein to Promote Lung Cancer Cell Stemness.Cancers · 2020Article
- Circular RNAs and their participation in stemness of cancer.Medical oncology (Northwood, London, England) · 2020Review
- Quantitative site- and structure-specific N-glycoproteomics characterization of differential N-glycosylation in MCF-7/ADR cancer stem cells.Clinical proteomics · 2020Article
- Significance of cyclooxygenase-2, prostaglandin E2 and CD133 levels in sunitinib-resistant renal cell carcinoma.Oncology letters · 2019Article
- Cancer stem cells and nanotechnological approaches for eradication.Stem cell investigation · 2019Review
- Effects of Cetuximab and Erlotinib on the behaviour of cancer stem cells in head and neck squamous cell carcinoma.Oncotarget · 2018Article
- Connective tissue growth factor promotes temozolomide resistance in glioblastoma through TGF-β1-dependent activation of Smad/ERK signaling.Cell death & disease · 2017Article
- CD90 positive cells exhibit aggressive radioresistance in esophageal squamous cell carcinoma.Journal of thoracic disease · 2017Article
- Targeting cancer stem cells and signaling pathways by phytochemicals: Novel approach for breast cancer therapy.Seminars in cancer biology · 2016Review
- Clinical applications of mouse models for breast cancer engaging HER2/neu.Integrative cancer science and therapeutics · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer stem cells (CSCs) are a small subpopulation of tumor cells with capabilities of self-renewal, dedifferentiation, tumorigenicity, and inherent chemo-and-radio therapy resistance. Tumor resistance is believed to be caused by CSCs that are intrinsically challenging to common treatments. A number of CSC markers including CD44, CD133, receptor tyrosine kinase, aldehyde dehydrogenases, epithelial cell adhesion molecule/epithelial specific antigen, and ATP-binding cassette subfamily G member 2 have been proved as the useful targets for defining CSC population in solid tumors. Furthermore, targeting CSC markers through new therapeutic strategies will ultimately improve treatments and overcome cancer drug resistance. Therefore, the identification of novel strategies to increase sensitivity of CSC markers has major clinical implications. This review will focus on the innovative treatment methods such as nano-, immuno-, gene-, and chemotherapy approaches for targeting CSC-specific markers and/or their associated signaling pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.